Current and future options for the treatment of chemotherapy-induced anaemia

Bibliography

• GROOPMAN JE, ITRI LM: Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl. Cancer Inst. (1999) 91(19):1616-1634.
   PubMed Web of Science ®Google Scholar
• HARRISON LB, SHASHA D, WHITE C, RAMDEEN B: Radiotherapy-associated anemia: the scope of the problem. Oncologist (2000) 5(Suppl. 2):1-7.
   Google Scholar
• MILLER CB, JONES RJ, PIANTADOSI S, ABELOFF MD, SPIVAK JL: Decreased erythropoietin response in patients with the anemia of cancer. N. Engl. J. Med. (1990) 322(24):1689-1692.
   PubMed Web of Science ®Google Scholar
• MEANS RT: Recent developments in the anemia of chronic disease. Curr. Hematol. Rep. (2003) 2(2):116-121.
   PubMedGoogle Scholar
• CERSOSIMO RJ, JACOBSON DR: Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia. Ann. Pharmacother. (2006) 40(1):58-65.
   PubMed Web of Science ®Google Scholar
• EGRIE JC, DWYER E, BROWNE JK, HITZ A, LYKOS MA: Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. Hematol. (2003) 31(4):290-299.
   PubMed Web of Science ®Google Scholar
• BOKEMEYER C, AAPRO MS, COURDI A et al.: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur. J. Cancer (2004) 40(15):2201-2216.
   PubMed Web of Science ®Google Scholar
• RIZZO JD, LICHTIN AE, WOOLF SH et al.: Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood (2002) 100(7):2303-2320.
   PubMed Web of Science ®Google Scholar
• GLASPY JA, JADEJA JS, JUSTICE G et al.: Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br. J. Cancer (2002) 87(3):268-276.
   PubMed Web of Science ®Google Scholar
• GLASPY JA, JADEJA JS, JUSTICE G, FLEISHMAN A, ROSSI G, COLOWICK AB: A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer (2003) 97(5):1312-1320.
   PubMed Web of Science ®Google Scholar
• SCHWARTZBERG LS, YEE LK, SENECAL FM et al.: A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist (2004) 9(6):696-707.
   PubMed Web of Science ®Google Scholar
• WALTZMAN R, CROOT C, JUSTICE GR, FESEN MR, CHARU V, WILLIAMS D: Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 mcg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist (2005) 10(8):642-650.
   PubMed Web of Science ®Google Scholar
• SENECAL FM, YEE L, GABRAIL N et al.: Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 mcg every two weeks versus epoetin alfa 40,000 U weekly. Clin. Breast Cancer (2005) 6(5):446-454.
   PubMedGoogle Scholar
• GLAPSY J, VADHAN-RAJ S, PATEL R et al.: Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 study group trial. J. Clin. Oncol. (2006) 24(15):2290-2297.
   PubMed Web of Science ®Google Scholar
• SCHWARTZBERG L, SHIFFMAN R, TOMITA D, STOLSHEK B, ROSSI G, ADAMSON R: A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin. Ther. (2003) 25(11):2781-2796.
   PubMed Web of Science ®Google Scholar
• HERRINGTON JD, DAVIDSON SL, TOMITA DK, GREEN L, SMITH RE, BOCCIA RV: Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am. J. Health-Syst. Pharm. (2005) 62(1):54-62.
   PubMed Web of Science ®Google Scholar
• WU WK, MONTAGNE M: Darbepoetin versus epoetin. Am. J. Health-Syst. Pharm. (2005) 62(15):1552-1556.
   PubMed Web of Science ®Google Scholar
• PUJADE-LAURAINE E, RICHARD AJ, SAPEDE C, HAYWARD C: Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alfa, epoetin beta and darbepoetin alfa use in routine clinical practice. Oncol. Rep. (2005) 14(4):1037-1044.
   PubMed Web of Science ®Google Scholar
• STEENSMA DP, MOLINA R, SLOAN JA et al.: Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J. Clin. Oncol. (2006) 24(7):1079-1089.
   PubMed Web of Science ®Google Scholar
• CANON JL, VANSTEENKISTE J, BODOKY G et al.: Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J. Natl. Cancer Inst. (2006) 98(4):273-284.
   PubMed Web of Science ®Google Scholar
• LEYLAND-JONES B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. (2003) 4(8):459-460.
   PubMed Web of Science ®Google Scholar
• HENKE M, LASZIG R, RUBE C et al.: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet (2003) 362(9392):1255-1260.
   PubMed Web of Science ®Google Scholar
• BOHLIUS J, LANGENSIEPEN S, SCHWARZER G et al.: Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J. Natl. Cancer Inst. (2005) 97(7):489-498.
   PubMed Web of Science ®Google Scholar
• BOHLIUS J, WILSON J, BAYLISS S et al.: Epoetin and darbepoetin to treat cancer patients: updated meta-analysis results. Blood (2005) 106(11):222a.
   Google Scholar
• REED N, CHAN S, HAYWARD C, BURGER HU, TEN BOKKEL HUININK W: Impact of epoetin beta on the survival of anemic patients with ovarian cancer receiving platinum-based chemotherapy. J. Clin. Oncol. (2005) 23(16s):479s.
   Google Scholar
• HEDENUS M, VANSTEENKISTE J, KOTASEK D, AUSTIN M, AMADO RG: Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J. Clin. Oncol. (2005) 23(27):6941-6948.
   PubMed Web of Science ®Google Scholar
• BENNETT CL, LUMINARI S, NISSENSON AR et al.: Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med. (2004) 351(14):1403-1408.
   PubMed Web of Science ®Google Scholar
• ROSSERT J, CASADEVALL N, ECKARDT KU: Anti-erythropoietin antibodies and pure red cell aplasia. J. Am. Soc. Nephrol. (2004) 15(2):398-406.
   PubMed Web of Science ®Google Scholar
• MacDOUGALL IC: Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol. Dial. Transplant. (2005) 20(Suppl. 4):iv9-iv15.
   PubMedGoogle Scholar
• HEDENUS M, CANON JL, KOTASEK D et al.: Effects of dose adjustment rules on safety during erythropoietic therapy: a retrospective analysis of darbepoetin alfa administered either every 3 weeks or weekly. Blood (2005) 106(11):943a.
   Google Scholar
• KNIGHT R, DELAP RJ, ZELDIS JB: Lenalidomide and venous thrombosis in multiple myeloma. N. Engl. J. Med. (2006) 354(19):2079-2080.
   PubMed Web of Science ®Google Scholar
• STEAD RB, LAMBERT J, WESSELS D et al.: A synthetic peptide-based erythropoiesis stimulating agent (ESA) (Hematide), demonstrates dose dependent activity and is well tolerated in a Phase I single dose, dose escalating study in normal health volunteers. J. Clin. Oncol. (2005) 23(16s):773s.
   Google Scholar
• DULIEGE AM, MacDOUGALL I, DUNCAN N et al.: Hematide™, a synthetic peptide-based erythropoiesis stimulating agent (ESA), demonstrates erythropoietic activity in a Phase II single dose, dose escalating study in patients with chronic kidney disease (CKD). Blood (2005) 106(11):986a.
   Google Scholar
• MacDOUGALL IC: CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr. Hematol. Rep. (2005) 4(6):436-440.
   PubMedGoogle Scholar
• REIGNER B, JORDAN P, PANIER A, GLASPY J: CERA (continuous erythropoiesis receptor activator), a novel erythropoietic agent: dose-dependent response in Phase I studies. Proc. Am. Soc. Clin. Oncol. (2003) 22:732.
   Google Scholar
• DOUGHERTY FC, REIGNER B, JORDAN P, PANNIER A: CERA (continuous erythropoiesis receptor activator): dose-response, pharmacokinetics and tolerability in Phase I multiple ascending dose studies. Proc. Am. Soc. Clin. Oncol. (2004) 23:603.
   Google Scholar
• DMOSZYNSKA A, KLOCZKO J, ROKICKA M, HELLMANN A, SPICKA I: CERA (continuous erythropoiesis receptor activator) produces a dose-related response in patients with multiple myeloma: an exploratory Phase I-II dose-escalation study. Blood (2003) 102(11):503a.
   Google Scholar
• JAAKKOLA P, MOLE DR, TIAN YM et al.: Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (2001) 292(5516):468-472.
   PubMed Web of Science ®Google Scholar
• MARXSEN JH, STENGEL P, DOEGE K et al.: Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-α-prolyl-4-hydroxylases. Biochem. J. (2004) 381(3):761-767.
   PubMed Web of Science ®Google Scholar
• HSIEH M, LINDE S, METZGER M et al.: Chronic intermittent administration of HIF prolyl hydroxylase inhibitor significantly induces erythropoietin and increases total hemoglobin in normal rhesus macaques. Blood (2005) 106(11):169a.
   Google Scholar
• URQUILLA P, FONG A, OKSANEN S et al.: Upregulation of endogenous erythropoietin (EPO) in healthy subjects by inhibition of hypoxia inducible factor (HIF) prolyl hydroxylase. Blood (2004) 104(11):54a.
   Google Scholar
• ZHONG H, DE MARZO AM, LAUGHNER E et al.: Overexpression of hypoxia-inducible factor 1 α in common human cancers and their metastases. Cancer Res. (1999) 59(22):5830-5835.
   PubMed Web of Science ®Google Scholar
• ÖSTERBORG AC, DE BOER R, CLEMENS M et al.: A novel erythropoiesis-stimulating agent (AMG114) with 131-hour half-life effectively treats chemotherapy-induced anemia when administered as 200 mcg every 3 weeks. J. Clin. Oncol. (2006) 24(18s):499s.
   Google Scholar
• AUERBACH M, BALLARD H, TROUT JR et al.: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. (2004) 22(7):1301-1307.
   PubMed Web of Science ®Google Scholar
• TARANTOLO S, BOUDA DW: Early results from a novel treatment strategy for chemotherapy-related anemia: epoetin alfa 60,000 U SQ QW induction followed by 60,000 U SQ Q2W. Proc. Am. Soc. Clin. Oncol. (2004) 23:776.
   Google Scholar
• GROSBACH A, LANGER CJ, MONTOYA V, WILLIAMS D: Epoetin alfa 60,000 U QW followed by 80,000 U Q3W maintenance in patients with anemia and cancer receiving chemotherapy. Proc. Am. Soc. Clin. Oncol. (2004) 23:778.
   Google Scholar
• GLASPY JA: The development of erythropoietic agents in oncology. Expert Opin. Emerging Drugs (2005) 10(3):553-567.
   PubMedGoogle Scholar
• AMGEN: Aranesp® package insert. The Netherlands, Europe (2006).
   Google Scholar
• BOCCIA R, LIU D, SILBERSTEIN P et al.: Evaluating the effectiveness of darbepoetin alfa 300 mcg Q3W for the treatment of chemotherapy-induced anemia. J. Clin. Oncol. (2005) 23(16s):761s.
   Google Scholar